...
首页> 外文期刊>Journal of experimental & clinical cancer research : >Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia
【24h】

Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia

机译:抑制自噬可增强替加环素的选择性抗癌活性,从而克服其在治疗慢性粒细胞白血病中的耐药性

获取原文
           

摘要

Background Drug resistance and disease progression are still the major obstacles in the treatment of chronic myeloid leukemia (CML). Increasing researches have demonstrated that autophagy becomes activated when cancer cells are subjected to chemotherapy, which is involved in the development of drug resistance. Therefore, combining chemotherapy with inhibition of autophagy serves as a new strategy in cancer treatment. Tigecycline is an antibiotic that has received attention as an anti-cancer agent due to its inhibitory effect on mitochondrial translation. However, whether combination of tigecycline with inhibition of autophagy could overcome drug resistance in CML remains unclear. Methods We analyzed the biological and metabolic effect of tigecycline on CML primary cells and cell lines to investigate whether tigecycline could regulate autophagy in CML cells and whether coupling autophagy inhibition with treatment using tigecycline could affect the viabilities of drug-sensitive and drug-resistant CML cells. Results Tigecycline inhibited the viabilities of CML primary cells and cell lines, including those that were drug-resistant. This occurred via the inhibition of mitochondrial biogenesis and the perturbation of cell metabolism, which resulted in apoptosis. Moreover, tigecycline induced autophagy by downregulating the PI3K-AKT-mTOR pathway. Additionally, combining tigecycline use with autophagy inhibition further promoted the anti-leukemic activity of tigecycline. We also observed that the anti-leukemic effect of tigecycline is selective. This is because the drug targeted leukemic cells but not normal cells, which is because of the differences in the mitochondrial biogenesis and metabolic characterization between the two cell types. Conclusions Combining tigecycline use with autophagy inhibition is a promising approach for overcoming drug resistance in CML treatment.
机译:背景技术耐药性和疾病进展仍然是治疗慢性粒细胞白血病(CML)的主要障碍。越来越多的研究表明,当癌细胞进行化学疗法时,自噬被激活,这与耐药性的发展有关。因此,将化学疗法与自噬抑制相结合是癌症治疗的新策略。 Tigecycline是一种抗生素,因其对线粒体翻译的抑制作用而作为抗癌剂受到关注。然而,替加环素与自噬抑制作用的结合是否可以克服CML的耐药性尚不清楚。方法我们分析了替加环素对CML原代细胞和细胞系的生物学和代谢作用,以研究替加环素是否可以调节CML细胞的自噬,以及将自噬抑制与替加环素治疗相结合是否会影响药物敏感性和耐药性CML细胞的生存能力。结果替加环素抑制了CML原代细胞和细胞系的活力,包括耐药性。这是通过抑制线粒体生物发生和扰动细胞代谢而发生的,从而导致细胞凋亡。此外,替加环素通过下调PI3K-AKT-mTOR途径诱导自噬。另外,将替加环素的使用与自噬抑制相结合进一步促进了替加环素的抗白血病活性。我们还观察到,替加环素的抗白血病作用是选择性的。这是因为该药物靶向白血病细胞而不靶向正常细胞,这是由于两种细胞类型之间线粒体生物发生和代谢特征的差异。结论结合使用替加环素和自噬抑制是克服CML治疗耐药性的有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号